Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin for MHE and SIBO in Cirrhosis
NCT02439307Terminated
- Sponsor
- Coordinación de Investigación en Salud
- Start
- Feb 2017
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in hepatic encephalopathy (HE) and small intestinal bacterial overgrowth (SIBO) comparing Rifaximin with Placebo (2 arms). Primary endpoint: Reversal of small intestinal bacterial overgrowth at 2 weeks. Started Feb 2017; status: terminated.
02
Drugs
rifaximin
03
Conditions
hepatic encephalopathy (HE)small intestinal bacterial overgrowth (SIBO)
Beyond the preview
Go deeper on NCT02439307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02439307.